Compare ASIC & PRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ASIC | PRCT |
|---|---|---|
| Founded | 2018 | 2009 |
| Country | United States | United States |
| Employees | 203 | N/A |
| Industry | Property-Casualty Insurers | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | 2025 | 2021 |
| Metric | ASIC | PRCT |
|---|---|---|
| Price | $26.39 | $16.86 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 5 | 14 |
| Target Price | ★ $29.10 | $21.64 |
| AVG Volume (30 Days) | 51.7K | ★ 1.2M |
| Earning Date | 10-21-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 23.44 | 1.71 |
| EPS | ★ 1.18 | N/A |
| Revenue | ★ $424,339,000.00 | $308,054,000.00 |
| Revenue This Year | $27.91 | $28.36 |
| Revenue Next Year | $25.28 | $20.60 |
| P/E Ratio | $22.21 | ★ N/A |
| Revenue Growth | 23.41 | ★ 37.22 |
| 52 Week Low | $16.35 | $16.67 |
| 52 Week High | $29.00 | $38.11 |
| Indicator | ASIC | PRCT |
|---|---|---|
| Relative Strength Index (RSI) | 44.42 | 43.29 |
| Support Level | $18.75 | $16.89 |
| Resistance Level | $27.22 | $29.12 |
| Average True Range (ATR) | 0.80 | 0.86 |
| MACD | -0.30 | -0.09 |
| Stochastic Oscillator | 11.16 | 34.47 |
Ategrity Specialty Insurance Co Holdings is a specialty property and casualty insurance holding company focused on the excess and surplus market for small to medium-sized businesses (SMBs) across the United States. Operating through its subsidiaries, the company underwrites small and medium-sized commercial risks across selected industry verticals, including Retail, Real Estate, Hospitality, and Construction. Its operating model uses a technology-driven method to standardize, simplify, and, where appropriate, automate these transactions. The group distributes its products through licensed surplus lines brokers and wholesale agents.
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.